Treatment of metabolic diseases
Employees: 11-50
Founded date: 2009
Investors 1
| Date | Name | Website |
| 02.11.2022 | IPF Partne... | ipfpartner... |
Mentions in press and media 4
| Date | Title | Description |
| 25.06.2021 | Poxel : présente les résultats de deux études cliniques sur son activateur direct de l'AMPK kinase, le PXL770, au Congrès International sur le Foie (International Liver CongressTM) 2021 | Press Release Poxel Presents Results of Two Clinical Studies on its Direct AMP Kinase Activator, the PXL770, at the International Liver Congress (ILC)TM 2021 Pr. Kenneth Cusi presented the results of the STAMP- NAFLD 12-week, randomized, co... |
| 23.06.2021 | Poxel announces the approval of Twymeeg Poxel, within Andera Partners’ portfolio, and Sumitomo Dainippon Pharma Announce the Approval of TWYMEEG® (Imeglimin hydrochloride) for the Treatment of Type 2... | TWYMEEG® is a first-in-class drug with a unique dual mechanism of action for the treatment of Type 2 Diabetes across the continuum of the current treatment paradigm, both as a monotherapy or as an add-on to other glucose lowering therapies.... |
| 25.03.2021 | POXEL Poxel : Announces availability of its 2020 Universal Registration Document | Download as PDF March 25, 2021 Lyon, France, March 25, 2021 - POXEL S.A. (Euronext - POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes a... |
| 20.11.2020 | Vivek Ramaswamy’s Metavant hits a brick wall, abandoning a lead program for diabetes. And there’s nothing visible left to see here | Just a few years after Vivek Ramaswamy’s epic Alzheimer’s fail, another one of his startups is cutting its losses because of a high-risk endeavor — this time on the diabetes front — didn’t pan out. Metavant, Ramaswamy’s biotec... |